ArticleCancer medicine2017
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013.
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Survival of Patients With Cervical Cancer Treated With Definitive Radiotherapy or Concurrent Chemoradiotherapy According to Histological Subtype: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- In Reply.Deutsches Arzteblatt international · 2026Article
- Pathological outcomes in women with cervical adenocarcinomaFrontiers in oncology · 2026Article
- Trends in cervical cancer incidence in the Netherlands: A join-point and age-period-cohort analysis (1989-2023).International journal of cancer · 2026Article
- Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.International journal of cancer · 2025Article
- Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma.Translational oncology · 2025Article
- Site-agnostic PARP-inhibitor maintenance therapy of advanced stageGynecologic oncology reports · 2024Article
- Article
- Article
- Global Cervical Cancer Incidence by Histological Subtype and Implications for Screening Methods.Journal of epidemiology and global health · 2024Article
- Epidemiology of Cervical Cancer in the Caribbean.Cureus · 2023Review
- Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.Cancer medicine · 2023Article
- The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.Gynecologic oncology · 2023Article
- Molecular correlates of invasion pattern in HPV-associated endocervical adenocarcinoma: emergence of two distinct risk-stratified tiers.Histopathology · 2023Article
- Atypical glandular cells and development of cervical cancer: Population-based cohort study.International journal of cancer · 2022Article
- Performance of three colposcopic images for the identification of squamous and glandular cervical precursor neoplasias.Archives of gynecology and obstetrics · 2022Article
- Added value of radiomics analysis in MRI invisible early-stage cervical cancers.The British journal of radiology · 2022Article
- 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells.Bioengineered · 2022Article
- Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status.Virchows Archiv : an international journal of pathology · 2022Article
- Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the developed world, the incidence of cervical squamous cell carcinoma has decreased, however, the incidence of adenocarcinoma in situ (AIS) and invasive adenocarcinoma increased, predominantly in young females. The goal of this study was to evaluate the most recent incidence rates of AIS, adenocarcinoma, and squamous cell carcinoma of the uterine cervix in the Netherlands in 2004-2013. By using Dutch national pathology and cancer registries, we calculated European standardized incidence rates (ESR) and estimated annual percentage changes (EAPC) for AIS during 2004-2013 and for invasive cervical carcinomas during 1989-2013. For AIS, presence or absence of concomitant cervical intraepithelial neoplasia (CIN) was explored. The estimated annual percentage change (EAPC) of squamous cell carcinoma decreased significantly in 1989-2013, predominantly in 1989-2003. The EAPC of invasive adenocarcinoma decreased in 1989-2003, but remained stable in 2004-2013. The EAPC of AIS increased significantly, predominantly in women of 25-39 years old. Of these AIS cases, 58.9% had concomitant CIN and AIS with concomitant CIN showed a significantly higher EAPC compared to AIS without CIN. Our conclusion is that despite a nationwide screening program for cancer of the uterine cervix, the incidence of adenocarcinoma in the Netherlands remained stable during 2004-2013 and the incidence of adenocarcinoma in situ increased. This was most predominant in cases with concomitant CIN and in younger females. The incidence of squamous cell carcinoma decreased in the same timeframe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.